UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.45 USD
+0.01 (0.69%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.45 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Brokerage Reports
UNITY Biotechnology, Inc. [UBX]
Reports for Purchase
Showing records 81 - 100 ( 103 total )
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Getting at the Essence with Senescence; Initiating OP & $4 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
UBX1325 Advances to Phase 2, as Senolytics Platform Takes Shape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
UBX1325 Phase 1 SAD Study Reinforces Validation for Senolytics
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Lead Senolytics Candidate UBX1325 Continues Validation with 12-Week Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
We are reiterating our Neutral rating and our 12-month target price of $4/share.
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
UBX1325 Visual Acuity and CST Drive Program; Phase 1 Data Expected YE21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Positive KOL Perspectives Support UBX1325 Senolytic Innovation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Beyond Anti-VEGF Early Phase 1 Data Supports Senolytic Benefit
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Senolytics Platform Offers Novel Targets Within Retinopathies; Initiating With Buy Rating and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A